1. Home
  2. HXHX vs AKTX Comparison

HXHX vs AKTX Comparison

Compare HXHX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.53

Market Cap

16.8M

Sector

Industrials

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.35

Market Cap

17.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
AKTX
Founded
2003
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8M
17.2M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
HXHX
AKTX
Price
$0.53
$0.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
375.5K
1.3M
Earning Date
04-30-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$25,571,810.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.32
52 Week High
$6.29
$1.73

Technical Indicators

Market Signals
Indicator
HXHX
AKTX
Relative Strength Index (RSI) 36.39 28.28
Support Level $0.49 $0.42
Resistance Level $0.64 $0.50
Average True Range (ATR) 0.10 0.08
MACD 0.01 -0.00
Stochastic Oscillator 10.67 11.86

Price Performance

Historical Comparison
HXHX
AKTX

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: